BPC-157 Side Effects at Different Dosage Levels

Individuals looking for information regarding the BPC-157 side effects may perhaps be asking themselves about the possibility of adverse reactions. The truthful response that can be found in literature is surprisingly straightforward: Scientific studies that have been conducted on animals revealed no negative or side effects. However, this response must be clarified greatly. Noting that animal research led to no detectable side effects does not imply that the compound may also be considered safe in the case of humans. The current page explains the extent of the measurements, what has not been observed, and the importance of this clarification.

BPC-157 Side Effects - What Published Studies Report

Adverse Events in Rodent Models

Across the published BPC-157 literature, adverse effects were rarely reported at the doses used. Sikiric et al. (2010) reviewed the accumulated data and noted that no lethal dose (LD50) had been identified and no organ toxicity had been observed in the studies reviewed (PMID 20166993).

This observation is atypical for a substance with biological activity. Usually, such substances demonstrate dose-dependent adverse effects. The fact that BPC-157 clinical trials show no dangerous effects can mean either that the substance is really safe at levels at which it was studied, or that not enough tests have been done. Our choice is based on our opinion that the latter is more likely.

High-Dose Observations in Toxicology Screens

BPC-157 has not seen formal dose escalation toxicology studies like those conducted by pharmaceutical companies prior to human trials. The maximum published dosages are rather insignificant in terms of toxicity. Data indicates a high number of studies using the dosage of 10 mcg/kg and there are also many studies that report both 10 mcg/kg and 10 ng/kg. None of the studies put a systematic approach into finding the dosage at which adverse effects start appearing.

Acute toxicity testing in the regular process of drug development involves doses that are 10 to 100 times higher than the expected therapeutic dosage. Subchronic and chronic toxicity studies are performed in which animals are treated for a period of time ranging from few weeks to few months. This type of research has not been carried out for the BPC-157.

Dose-Dependent Effects in Animal Data

A clear trend is seen in the above: none of the analyzed studies found negative effects. However, a trend like that must not be celebrated, and rather, it requires an explanation.

Low-Dose Range Findings

No study showed weight reduction, variations in behavior, impairment in the organs, or deaths in rats after administration of the basic research dose of 10 mcg/kg (approximately 2.5 micrograms for a rat weighing 250 g). The lower dose of 10 ng/kg, tested in a number of studies, also failed to produce any adverse effects.

These findings relate to a compound that was tolerated well in the amounts being assessed, but while the experiments are targeted at establishing efficacy (strength of tendons, rate of healing, size of injury), they were not aimed at evaluating safety. Statistics about safety, such as biochemical blood tests, organ histopathology at the end of the study, or behavioral tests, were not of primary importance.

High-Dose and Repeated-Dose Findings

There is a scarcity of serious high dose data in the existing literature. In toxicology the term 'high dose' is applied to dosages that exceed the expected efficacy level, as a part of the investigation strategy to determine the limit for the abstaining effect dose. Only there are no studies on BPC-157 concerning what can be considered high doses. It must be stressed that the maximum dose used was still within the range of dose efficacy testing, but not safety testing.

Results from repeated-dose studies are restricted to conventional daily protocols, which only take a week to two weeks. The data concerning safety during long-term repeated doses, which is required to measure risks associated with chronic use, does not exist.

Known Gaps in Safety Data

No Phase I Human Safety Trial

Phase I trials represent an initial phase in human trials and are tailored to study safety, tolerability, and pharmacokinetics. They involve a small number of healthy volunteers and consist of a progressive increase in dosage and strict observation. Up to this moment, no published attempts have been made at undertaking a Phase I trial on the substance BPC-157, meaning that the necessary basic safety information about it, the maximum tolerated dosage and the dose-limiting toxicities, as well as the most frequently observed side effects, are still not available.

No Long-Term Toxicology in Any Species

The normal preclinical drug development process comprises toxicology studies lasting 28 days, 90 days, and occasionally 6 months in at least two animal species (a rodent and a non-rodent). Such studies entail the examination of many parameters, including the animal's body weight, food intake, signs of disease, hematological and clinical chemical parameters, urinalysis, organ weights, and gross and microscopic pathology. A toxicology program as detailed and thorough as the one described above is not available for BPC-157.

The existing BPC-157 studies are specifically pharmacological studies that investigate whether this peptide helps with healing. They are not to be confused with toxicology studies examining the safety of the peptide. This distinction is critical to understand, but is often ignored in public discourse.

Drug Interaction Data Does Not Exist

There are no studies that investigate the interaction between BPC-157 and commonly used drugs. Individuals looking to try BPC-157 may be taking NSAIDs for pain treatment, anticoagulants, antibiotics, or other pharmaceutical drugs. The interaction of BPC-157 with other medications remains completely unknown. This indeed is a significant concern as medication interaction is a major cause of undesirable events in clinical practice.

What "Side Effects" Means Without Human Trials

Rodent Observations Are Not Human Side Effects

Should a thorough toxicological investigation have been conducted in rats, which discovered definite harmful effects, these results would not be able to estimate if there could be side effects on humans. Differences between species in metabolism, physiology, as well as receptor expression implies that rodent toxicity cannot be transferred into human toxicity.

This means that just because rats did not exhibit negative symptoms, it does not necessarily confirm that humans will not be affected.

Reporting Bias in Preclinical Literature

Preclinical investigations are usually less inclined to report disappointing results. For instance, if certain animals in a research using BPC-157 exhibit a certain weight loss or unpleasant behavioral changes for a short period, such results might not be mentioned in an article focused on investigating health of tendons. It is a wide-spread phenomenon observed in most publications in preclinical pharmacology. It shows that the finding “nothing bad happened” might be due to reporting glitches, rather than the fact that nothing negative was noted.

There is no proof of the adverse effects that have been seen and hidden from the public. What we have observed is that the design of these studies did not facilitate the acquisition of comprehensive safety data.